FDA Approves Venetoclax for CLL and SLL
Approval is based on results from the CLL14 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Avelumab Plus Axitinib for Renal Cell Carcinoma
Approval is based on results from the JAVELIN Renal 101 study
Next Generation Profiling of the Cancer Cell Line Encyclopedia
Acceleration of cancer research by use of model cancer cell lines
How to Improve Access to Expertise in Cancer Imaging
Practical steps to improve situation in the context of changing landscape of cancer imaging
FDA Approves Ramucirumab for Hepatocellular Carcinoma
Approval is based on results from the REACH‑2 study
EMA Recommends Granting a Marketing Authorisation for New Biosimilar Pegfilgrastim
Grasustek received a positive opinion for prophylaxis against neutropenia in adult patients treated with cytotoxic chemotherapy
FDA Approves Ado-trastuzumab Emtansine for Early Breast Cancer
It is indicated in the adjuvant treatment of patients with HER2-positive tumours who have residual invasive disease after pre-operative systemic treatment
EMA is Updating the Prescribing Information for Lapatinib
Re-analysis of data on use of breast cancer medicine lapatinib following treatment with trastuzumab
EMA Recommends Refusal of a Marketing Authorisation for Cabazitaxel Teva
Developed as a hybrid medicine, it was expected to be used for treatment of prostate cancer
FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation
It is approved in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy
Patients aged 75-79 years at higher risk of distant recurrence than patients aged 70-74 years in the older population (>70 years) of patients with early stage breast cancer despite higher competing mortality
Risk of recurrence and competing mortality in older patients
EMA Recommends an Extension of Therapeutic Indication for Olaparib
New indication concerns maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian cancer